History

Letrozole is a genuine, fully approved prescription drug marketed as Femara by Novartis. The FDA first approved it in July 1997 for advanced breast cancer in postmenopausal women progressing after antiestrogen therapy; in 2001 it gained first-line approval for HR-positive or unknown locally advanced/metastatic disease, and on April 30, 2010 it was converted from accelerated to full approval for adjuvant and extended-adjuvant treatment of postmenopausal women with HR-positive early breast cancer. Its core oncology use is in postmenopausal women, since AIs are generally ineffective as monotherapy in premenopausal women whose ovaries can override the estrogen suppression. It is also widely used off-label — and guideline-supported but not FDA-approved — for ovulation induction in anovulatory infertility, especially PCOS. (Note: the Cohen 2002 abstract states a 1998 first approval, but FDA and other regulatory/news records place it in July 1997.)

Letrozole, sold as Femara, is an oral, nonsteroidal third-generation aromatase inhibitor (AI) — a legitimate, well-studied drug with a strong evidence base in both oncology and fertility medicine. It is important to be precise about what it is: letrozole is not a peptide, not a SERM (selective estrogen receptor modulator like tamoxifen), and not an anabolic steroid. It works by shutting down the enzyme that makes estrogen, lowering circulating estradiol throughout the body. In bodybuilding circles it is used off-label to blunt the estrogen produced when aromatizable androgens are taken — a practice that is unapproved, unstudied in that population, banned in sport, and capable of real harm. This page is educational and harm-reduction oriented; it contains no dosing, cycles, stacks, or post-cycle protocols, and no sourcing information.

What it is

Letrozole is a nonsteroidal, reversible, competitive third-generation aromatase inhibitor — a triazole compound. Aromatase (CYP19A1) is the cytochrome-P450 enzyme that converts androgens into estrogens (testosterone to estradiol; androstenedione to estrone), mostly in peripheral tissue such as fat, muscle, gonads, and brain. Letrozole binds the heme iron of the aromatase CYP450 unit, blocking estrogen synthesis.

In postmenopausal women it suppresses circulating estradiol, estrone, and estrone-sulfate by roughly 75–95% from baseline, reaching near-maximal suppression within 2–3 days. It does not affect adrenal corticosteroid or aldosterone synthesis at therapeutic doses. Because it lowers estrogen, it reduces the negative feedback on the hypothalamic-pituitary axis, raising FSH and LH. That single mechanism underlies both its medical fertility use (more FSH drives follicle growth) and its appeal in male PED contexts (raising endogenous gonadotropins and testosterone while controlling estrogen). Crucially, letrozole does not block estrogen receptors — that is the mechanism of SERMs such as tamoxifen, a different drug class.

The claims

Medically, letrozole is used for (1) adjuvant, extended-adjuvant, and metastatic HR-positive breast cancer in postmenopausal women, and (2) off-label ovulation induction in anovulatory infertility and PCOS. Investigational uses (endometriosis, gynecomastia, short-stature/growth contexts) are off-label and less established.

In the PED context (off-label, illicit, and unapproved), anabolic-androgenic steroid users take AIs like letrozole as an “ancillary” to suppress the estrogen produced when aromatizable androgens convert to estradiol. The stated goals are to prevent or treat gynecomastia and estrogenic water retention, and to raise endogenous testosterone and gonadotropins. Letrozole is one of the more potent AIs, which makes “estrogen crashing” — driving estradiol too low — a real and frequently self-reported problem. None of these uses are evidence-based protocols, and no doses, cycles, stacks, or PCT regimens are provided here.

What the evidence actually shows

The human evidence base in the drug’s medical indications is large and robust.

Breast cancer — superiority over tamoxifen (BIG 1-98): This head-to-head adjuvant trial in postmenopausal women with receptor-positive early breast cancer found letrozole significantly improved disease-free survival versus tamoxifen (hazard ratio ~0.81–0.82). (Thürlimann et al., NEJM 2005;353:2747-2757; PMID 16382061.)
Extended adjuvant therapy (MA.17R): Continuing letrozole to 10 total years (5 more after an initial 5 years of an AI) further reduced recurrence and contralateral breast cancer and improved 5-year disease-free survival (95% vs 91%) — but increased bone toxicity, with more fractures (14% vs 9%) and more new-onset osteoporosis (11% vs 6%). Overall survival was not significantly improved (93% vs 94%; HR 0.97, P=0.83). (Goss et al., NEJM 2016;375:209-219; PMID 27264120.)
Infertility / PCOS (landmark Legro trial): In a double-blind RCT of 750 women with PCOS, letrozole produced higher cumulative live-birth rates than clomiphene (27.5% vs 19.1%; rate ratio 1.44) and higher cumulative ovulation rates (61.7% vs 48.3%). This drove its adoption as a first-line ovulation-induction agent in PCOS. (Legro et al., NEJM 2014;371:119-129; PMID 25006718.)

On PED use specifically: there are no rigorous human trials validating letrozole’s safety or efficacy for bodybuilding/PED “estrogen management.” Evidence in that population is anecdotal — the oncology and fertility data above do not validate that practice.

Legal and regulatory status

US — prescription (Rx) drug. Letrozole is legal to possess and use with a valid prescription and is not a controlled substance. Selling or distributing it without authorization, or marketing “research chemical” letrozole for human use, is unlawful (unapproved-drug / misbranding territory). The other anti-estrogens commonly seen alongside it — tamoxifen, anastrozole, exemestane, clomiphene — are likewise Rx and non-controlled. Aromatase inhibitors and SERMs are not scheduled.

For legal clarity, it helps to contrast the compounds that come up alongside it:

Mesterolone (Proviron) and fluoxymesterone (Halotestin) are anabolic-androgenic steroids — Schedule III controlled substances in the US under the Anabolic Steroid Control Act (21 CFR 1308.13). Letrozole, SERMs, and AIs are not scheduled.
DNP (2,4-dinitrophenol) is NOT approved for human consumption in any form. In 1938 the FDA declared DNP unfit and unsafe for human use; it has a long, well-documented history of fatal poisonings (it uncouples oxidative phosphorylation, producing uncontrolled metabolic heat). It is sold illegally as a “fat-burner,” is not a legitimate drug, and has no antidote.

Anti-doping (WADA 2026 Prohibited List, in force January 1, 2026). Letrozole is prohibited at all times (in- and out-of-competition) under S4, “Hormone and Metabolic Modulators.”

Aromatase inhibitors — S4 names letrozole, anastrozole, exemestane, formestane, and testolactone, among others.
Anti-estrogenic substances and SERMs — S4 names clomifene, tamoxifen, toremifene, raloxifene, and fulvestrant, among others.
2026 additions to S4 relevant here: α-naphthoflavone (7,8-benzoflavone) is now listed as an example of an aromatase inhibitor, and BAM15 is listed as an example of an AMP-activated protein kinase (AMPK) activator — it is a mitochondrial uncoupler. Both were flagged as appearing in supplements and “research chemicals.” (Verified via the USADA 2026 advisory.)
Insulin is prohibited under S4 (insulins and insulin-mimetics).

For context: anabolic agents (steroids such as mesterolone and fluoxymesterone) fall under S1. T3 / thyroid hormone is not currently on the WADA Prohibited List.

Safety

Estrogen deprivation drives the main harms of letrozole and the AI class.

Bone: bone loss, osteopenia/osteoporosis, and increased fracture risk — clearly shown in MA.17R (14% vs 9% fractures; 11% vs 6% new osteoporosis), because estrogen is bone-protective.
Joints and muscle: arthralgia, joint stiffness, and myalgia.
Lipids / cardiovascular: adverse lipid changes and cardiovascular signals.
Other: hot flashes, fatigue, and mood effects. In men using it off-label, crashing estradiol can cause joint pain, low libido, erectile dysfunction, lethargy, and bone-density loss — estradiol is essential for male bone, libido, and lipids, so “crashing” it with an AI is genuinely harmful, not benign.
Pregnancy: letrozole is a teratogen and is contraindicated in pregnancy. Its ovulation-induction use is deliberately timed pre-conception specifically to avoid fetal exposure.

Why PED self-experimentation around letrozole is dangerous comes down in large part to the compounds users combine with it:

DNP (2,4-dinitrophenol) — the most lethal item in this space. DNP kills people. It uncouples mitochondrial oxidative phosphorylation, so the energy that would make ATP is released as heat, causing runaway, fatal hyperthermia (body temperatures reported up to ~44 °C / 111 °F), tachycardia, profuse sweating, agitation, and multi-organ failure. There is no antidote and no established safe dose — deaths occur even at “recommended” amounts, sometimes hours after the last dose. Management is cooling and supportive care only, and fatalities are documented including in recent decades.
Insulin (used non-diabetically for an “anabolic”/nutrient-partitioning effect): profound, life-threatening hypoglycemia, seizures, irreversible brain injury, and death — especially without carbohydrate monitoring; a recognized cause of bodybuilder fatalities.
SERMs (tamoxifen, clomiphene, raloxifene): venous thromboembolism / clotting risk (DVT, PE, stroke), visual disturbances (clomiphene), hot flashes, and mood effects; tamoxifen carries endometrial-cancer risk in long-term oncology use.
T3 / liothyronine (thyroid hormone, used for fat loss): cardiac risk (tachyarrhythmias, atrial fibrillation, palpitations, increased cardiac workload), suppression of the thyroid axis with a hypothyroid rebound on cessation, bone loss with chronic excess, and muscle catabolism.

Bottom line

Letrozole is a legitimate, FDA-approved drug with a strong oncology and fertility evidence base — a nonsteroidal, reversible aromatase inhibitor, not a peptide and not a SERM. But it is potent at estrogen suppression and carries real bone, lipid, and joint consequences, and its bodybuilding/PED use to manipulate estrogen is off-label, unapproved, unstudied in that population, banned in sport (WADA S4), and capable of genuine harm — especially the sexual, mood, and bone effects of crashing estrogen in men. The broader “PED-support” stack it gets grouped with — DNP, insulin, T3 — contains some of the most acutely lethal substances in this space, DNP above all, which kills through unstoppable hyperthermia and has no antidote. Any use should be physician-supervised.

Evidence grade: Strong human.

Letrozole (Femara)